Join us   Log in  

PHARMASPIRE - Volume 12, Issue 4, October- December, 2020

Pages: 117-120

Date of Publication: 10-Jun-2022

Print Article   Download XML  Download PDF

Mini review on potentially reported adverse effects of drugs used for chronic kidney disease

Author: Simranjeet Kaur, Gurpreet Kaur, Amandeep Singh

Category: Pharmaceutics


Chronic kidney disease (CKD) is a progressive, irreversible decline in renal function in which body’s ability to maintain metabolic and fluid and electrolyte balance fails, resulting in uremia or azotemia. It is not a single disease and associated with different medical conditions such as diabetes, hypertension, and anemia; even though it is caused by primary kidney disease (e.g., glomerular diseases, tubulointerstitial diseases, obstruction, and polycystic kidney disease). This paper provides different stages of CKD estimated based on glomerular filtration rate and provides drug treatment used for CKD with their adverse effects. It also provide brief about treatment of end-stage kidney disease.

Keywords: Acute kidney injury, Chronic kidney disease, Parathyroid hor mone, Vitamin D receptor antagonists


1. Gerogianni SK, Babatsikou FP. Psychological aspects in chronic renal failure. Health Sci J 2014;8:205-14.

2. Leung DK. Psychosocial aspects in renal patients. Perit Dial Int 2003;23:90-4.

3. Levey AS, De Jong PE, Coresh J, El Nahas M, Astor BC, Matsushita K, et al. The definition, classification, and prognosis of chronic kidney disease: A KDIGO controversies conference report. Kidney Int 2011;80:17-28.

4. Centers for Disease Control and Prevention. National Chronic Kidney Disease Fact Sheet: General Information and National Estimates on Chronic Kidney Disease in the United States, 2010. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2010.

5. Emara SS, Alzaylai AA. Renal failure in burn patients: A review. Ann Burns Fire Disasters 2013;26:12-5.

6. Russcher M, Koch B, Nagtegaal E, Van der Putten K, Ter Wee P, Gaillard C. The role of melatonin treatment in chronic kidney disease. Front Biosci (Landmark Ed) 2012;17:2644-56.

7. Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004;6:659-63.

8. Combe C, McCullough KP, Asano Y, Ginsberg N, Maroni BJ, Pifer TB. Kidney disease outcomes quality initiative (K/DOQI) and the dialysis outcomes and practice patterns study (DOPPS): Nutrition guidelines, indicators, and practices. Am J Kidney Dis 2004;44:39-46.

9. Wilcox CS. Metabolic and adverse effects of diuretics. Semin Nephrol 1999;19:557-68.

10. Palmer BF. Metabolic complications associated with use of diuretics. Semin Nephrol 2011;31:542-52.

11. Brater DC. Diuretic therapy. N Engl J Med 1998;339:387-95.

12. Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS. Renal considerations in angiotensin converting enzyme inhibitor therapy: A statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Circulation 2001;16:1985-91.

13. Hou FF, Zhang X, Zhang GH, Xie D, Chen PY, Zhang WR, et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med 2006;354:131-40.

14. Tomlinson LA, Holt SG, Leslie AR, Rajkumar C. Prevalence of ambulatory hypotension in elderly patients with CKD stages 3 and 4. Nephrol Dial Transplant 2009;12:3751-5.

15. Toto RD, Mitchell HC, Lee HC, Milam C, Pettinger WA. Reversible renal insufficiency due to angiotensin converting enzyme inhibitors in hypertensive nephrosclerosis. Ann Intern Med 1991;7:513-9.

16. Lapi F, Azoulay L, Yin H, Nessim SJ, Suissa S. Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: Nested case-control study. BMJ 2018;346:e8525.

17. Hahn K, Ejaz AA, Kanbay M, Lanaspa MA, Johnson RJ. Acute kidney injury from SGLT2 inhibitors: Potential mechanisms. Nat Rev Nephrol 2016;12:711-2.

18. Palevsky PM, Zhang JH, Seliger SL, Emanuele N, Fried LF. Incidence, severity, and outcomes of AKI associated with dual renin-angiotensin system blockade. Clin J Am Soc Nephrol 2016;11:1944-53.

19. Tomlinson LA, Abel GA, Chaudhry AN, Tomson CR, Wilkinson IB, Roland MO, et al. ACE inhibitor and angiotensin receptor-II antagonist prescribing and hospital admissions with acute kidney injury: A longitudinal ecological study. PLoS One 2013;8:e78465.

20. Montford JR, Linas S. How dangerous is hyperkalemia? J Am Soc Nephrol 2017;28:3155-65.

21. Snitker S, Doerfler RM, Soliman EZ, Deo R, Peter WL, Kramlik S, et al. Association of QT-Prolonging medication use in CKD with electrocardiographic manifestations. Clin J Am Soc Nephrol 2017;12:1409-17. 22. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensinconverting-enzyme inhibition on diabetic nephropathy. The collaborative study group. N Engl J Med 1993;329:1456-62.

23. Brenner BM, Cooper ME, De Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.

24. Einhorn LM, Zhan M, Walker LD, Moen MF, Seliger SL, Weir MR, Fink JC. The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med 2009;169:1156-62.

25. Nakhoul GN, Huang H, Arrigain S, Jolly SE, Schold JD, Nally JV Jr., et al. Serum potassium, end-stage renal disease and mortality in chronic kidney disease. Am J Nephrol 2015;41:456-63.

26. Bjerre HL, Christensen JB, Buus NH, Simonsen U, Su J. The role of aliskiren in the management of hypertension and major cardiovascular outcomes: A systematic review and meta-analysis. J Hum Hypertens 2019;33:795-806.

27. Palmer BF, Colbert G, Clegg DJ. Potassium homeostasis, chronic kidney disease, and the plant-enriched diet. Kidney360 2020;1:65-71.

28. Kliger AS, Foley RN, Goldfarb DS, Goldstein SL, Johansen K, Singh A, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for anemia in CKD. Am J Kidney Dis 2013;62:849-59.

29. Kdigo AK. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl 2012;2:124-38.

30. Kovesdy CP, Kalantar-Zadeh K. Why is protein-energy wasting associated with mortality in chronic kidney disease? Semin Nephrol 2009;29:3-14.

31. Macdougall IC, Bock AH, Carrera F, Eckardt KU, Gaillard C, Van Wyck D, et al. FIND-CKD: A randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol Dial Transplant 2014;29:2075-84.

32. Macdougall IC. Iron supplementation in the non-dialysis chronic kidney disease (ND-CKD) patient: Oral or intravenous? Curr Med Res Opin 2010;26:473-82.

33. Hayat A. Safety issues with intravenous iron products in the management of anemia in chronic kidney disease. Clin Med Res 2008;6:93-102.

34. Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, Olgaard K, et al. Definition, evaluation, and classification of renal osteodystrophy: A position statement from kidney disease: Improving Global Outcomes (KDIGO). Kidney Int 2006;69:1945-53.

35. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl (2011) 2017;7:1-59.

36. Toussaint ND, Damasiewicz MJ. Do the benefits of using calcitriol and other vitamin D receptor activators in patients with chronic kidney disease outweigh the harms? Nephrology (Carlton) 2017;22:51-6.

37. Brancaccio D, Bommer J, Coyne D. Vitamin D receptor activator selectivity in the treatment of secondary hyperparathyroidism: Understanding the differences among therapies. Drugs 2007;67:1981-98.

38. Bailey RA, Wang Y, Zhu V, Rupnow MF. Chronic kidney disease in US adults with type 2 diabetes: An updated national estimate of prevalence based on kidney disease: Improving Global Outcomes (KDIGO) staging. BMC Res Notes 2014;7:415.

39. Dodds S. The how-to for type 2: An overview of diagnosis and management of type 2 diabetes mellitus. Nurs Clin North Am 20171;52:513-22.

40. Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-tomoderate renal insufficiency. Diabetes Care 2011;6:1431-7.

41. Lutz J, Jurk K, Schinzel H. Direct oral anticoagulants in patients with chronic kidney disease: Patient selection and special considerations. Int J Nephrol Renovasc Dis 2017;10:135-43.

42. Winocur L. Sitting here in limbo: The saga of end-stage renal failure and kidney transplantation in the United States. SSRN Electron J 2015;28:42-51.